tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Genmab price target lowered to $37 from $50 at H.C. Wainwright
The FlyGenmab price target lowered to $37 from $50 at H.C. Wainwright
2d ago
GMAB
Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
PremiumRatings
Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
2d ago
GMAB
Genmab downgraded to Underperform from Market Perform at Bernstein
PremiumThe Fly
Genmab downgraded to Underperform from Market Perform at Bernstein
10d ago
GMAB
Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns
PremiumRatings
Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns
10d ago
GMAB
Genmab announces EC marketing authorization for TIVDAK
PremiumThe Fly
Genmab announces EC marketing authorization for TIVDAK
10d ago
GMAB
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
14d ago
ALLR
ALNY
Genmab announces Tivdak approval in Japan
Premium
The Fly
Genmab announces Tivdak approval in Japan
14d ago
GMAB
Genmab’s Promising Oncology Prospects and Strategic Growth Catalysts Highlighted in Buy Rating
Premium
Ratings
Genmab’s Promising Oncology Prospects and Strategic Growth Catalysts Highlighted in Buy Rating
24d ago
GMAB
Genmab: Rina-S 120 mg/m2 led to ORR of 55.6% in Phase 2 RAINFOL trial
PremiumThe Fly
Genmab: Rina-S 120 mg/m2 led to ORR of 55.6% in Phase 2 RAINFOL trial
24d ago
GMAB
Genmab’s Promising Pipeline and Strategic Focus Justify Buy Rating Despite GEN3014 Setback
PremiumRatings
Genmab’s Promising Pipeline and Strategic Focus Justify Buy Rating Despite GEN3014 Setback
29d ago
GMAB
Genmab price target lowered to DKK 2,300 from DKK 2,400 at RBC Capital
PremiumThe Fly
Genmab price target lowered to DKK 2,300 from DKK 2,400 at RBC Capital
1M ago
GMAB
Genmab price target lowered to $45 from $50 at Truist
PremiumThe Fly
Genmab price target lowered to $45 from $50 at Truist
1M ago
JNJ
GMAB
William Blair upgrades Genmab with focus now on pipeline
PremiumThe FlyWilliam Blair upgrades Genmab with focus now on pipeline
1M ago
JNJ
GMAB
Genmab upgraded to Outperform from Market Perform at William Blair
Premium
The Fly
Genmab upgraded to Outperform from Market Perform at William Blair
1M ago
GMAB
Expectations for J&J Genmab opt-in lowered ahead of news, says Morgan Stanley
Premium
The Fly
Expectations for J&J Genmab opt-in lowered ahead of news, says Morgan Stanley
1M ago
JNJ
GMAB
JPMorgan expects ‘significant’ underperformance of Genmab shares
PremiumThe Fly
JPMorgan expects ‘significant’ underperformance of Genmab shares
1M ago
JNJ
GMAB
Genmab says J&J not exercising option on HexaBody-CD38
PremiumThe Fly
Genmab says J&J not exercising option on HexaBody-CD38
1M ago
JNJ
GMAB
Genmab falls 7% to $22.44 after J&J declines option on HexaBody-CD38
PremiumThe Fly
Genmab falls 7% to $22.44 after J&J declines option on HexaBody-CD38
1M ago
GMAB
Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment
PremiumThe Fly
Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment
2M ago
GMAB
Genmab upgraded to Outperform from Market Perform at Leerink
PremiumThe FlyGenmab upgraded to Outperform from Market Perform at Leerink
2M ago
JNJ
GMAB
Genmab A/S Navigates Global Economic and Geopolitical Challenges Amidst Market Volatility
Premium
Company Announcements
Genmab A/S Navigates Global Economic and Geopolitical Challenges Amidst Market Volatility
2M ago
Genmab upgraded to Neutral from Underperform at Exane BNP Paribas
Premium
The Fly
Genmab upgraded to Neutral from Underperform at Exane BNP Paribas
2M ago
JNJ
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >